title: Tissue pharmacokinetics of cefazolin in patients with lower limb infections.
abstract: Cefazolin, a first-generation cephalosporin with activity against methicillin-susceptible Staphylococcus aureus and streptococci, is often used to treat lower limb infections caused by these pathogens. Antimicrobial penetration is often limited in these patients due to compromised vasculature. Therefore, we sought to evaluate the exposure profile of cefazolin in serum and tissue in patients with lower limb infections. An in vivo microdialysis catheter was inserted into the tissue near the margin of the wound and constantly perfused with lactated Ringer's solution. Steady-state serum and tissue samples were simultaneously collected over a dosing interval. Serum protein binding was also assessed. Serum concentrations were analyzed by noncompartmental analysis. Tissue concentrations were corrected for percent in vivo recovery by using the retrodialysis technique. Seven patients with a mean weight of 95.45 ± 18.51 kg and a mean age of 54 ± 19 years were enrolled. Six patients received 1 g every 8 h, and one patient received 2 g every 24 h due to acute kidney injury. The free area under the curve from 0 to 8 h (fAUC0-8) values for serum and wound were 48.0 ± 18.66 and 56.35 ± 41.17 μg · h/ml, respectively, for the patients receiving 1 g every 8 h. The fAUC0-24 values for serum and wound were 1,326.1 and 253.9 μg · h/ml, respectively, for the single patient receiving 2 g every 24 h. The mean tissue penetration ratio (tissue/serum fAUC ratio) was 1.06. These data suggest that the amount of time that free-drug concentrations remain above the MIC (fT>MIC) for cefazolin in wound tissue is adequate to treat patients with lower limb infections.
authors.affiliation: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
authors.forename: Amira A
authors.initials: AA
authors.lastname: Bhalodi
authors.forename: Seth T
authors.initials: ST
authors.lastname: Housman
authors.forename: Ashley
authors.initials: A
authors.lastname: Shepard
authors.forename: James
authors.initials: J
authors.lastname: Nugent
authors.forename: David P
authors.initials: DP
authors.lastname: Nicolau
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D001798:Blood Proteins / Q000378:metabolism; D057785:Catheters; D002437:Cefazolin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D035002:Lower Extremity / Q000293:injuries / Q000382:microbiology; D008297:Male; D008826:Microbial Sensitivity Tests; D017551:Microdialysis; D008875:Middle Aged; D010539:Permeability; D011485:Protein Binding; D013203:Staphylococcal Infections / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D014950:Wounds, Penetrating / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D001798:Blood Proteins; D002437:Cefazolin
references.citation: Antimicrob Agents Chemother. 2012 Jun;56(6):3420-2
references.pmid: 22430966
references.citation: Diabet Foot Ankle. 2012;3:
references.pmid: 22577496
references.citation: Antimicrob Agents Chemother. 2010 Dec;54(12):5209-13
references.pmid: 20921312
references.citation: J Am Podiatr Med Assoc. 2013 Jan-Feb;103(1):2-7
references.pmid: 23328846
references.citation: Adv Drug Deliv Rev. 2000 Dec 15;45(2-3):189-216
references.pmid: 11108974
references.citation: Adv Drug Deliv Rev. 2000 Dec 15;45(2-3):125-48
references.pmid: 11108971
references.citation: Antimicrob Agents Chemother. 2011 Nov;55(11):5238-42
references.pmid: 21859939
references.citation: Br J Clin Pharmacol. 2007 Jun;63(6):753-7
references.pmid: 17223858
references.citation: BMC Anesthesiol. 2011 Feb 22;11:5
references.pmid: 21342529
references.citation: Antimicrob Agents Chemother. 1984 Sep;26(3):347-50
references.pmid: 6334490
references.citation: Antimicrob Agents Chemother. 2011 Sep;55(9):4028-32
references.pmid: 21670184
references.citation: J Infect Dis. 1973 Oct;128:Suppl:S341-6
references.pmid: 4744015
references.citation: Antimicrob Agents Chemother. 2008 Nov;52(11):3941-6
references.pmid: 18779352
references.citation: Ann Thorac Surg. 2007 Nov;84(5):1605-10
references.pmid: 17954069
references.citation: Antimicrob Agents Chemother. 2012 Dec;56(12):6160-5
references.pmid: 22985880
references.citation: Clin Pharmacokinet. 2005;44(9):895-913
references.pmid: 16122279
references.citation: Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2
references.pmid: 9455502